- Theralase Technologies (OTCQX:TLTFF) said on Tuesday that the company has expanded its Intellectual Property portfolio.
- Recently, Theralase has been granted a Brazilian patent for, “Metal-Based Thiopene Photodynamic Compounds and their Use”.
- The patent advances Theralase’s intellectual property portfolio internationally strengthening the patent portfolio around the Anti-Cancer Technology platform and further strengthens the extensive portfolio of patents already held by Theralase.
- Theralase’s lead PDC, TLD-1433, approved by Health Canada to be evaluated in a Phase II Non-Muscle Invasive Bladder Cancer clinical study (“Study II”).
- Currently, Study II has successfully been launched in 12 Clinical Study Sites (5 - Canadian and 7 – United States) with 41 patients treated.